Anirban Basu

Professor, Pharmacy
Professor, Health Systems and Population Health
Adjunct Professor, Economics
Stergachis Family Endowed Professor and Director, Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Pharmacy

Magnuson Health Sciences Center
Box 357630
1959 NE Pacific St.
Seattle, WA 98195-7630


Research Interests

Health econometrics; cost-effectiveness; comparative effectiveness and value of information analyses; quality of life; spill-over effects; substantive focus on cancer, mental health and diabetes


PhD Health Economics, Public Policy, University of Chicago, 2004

MS Biostatistics, University of North Carolina (Chapel Hill), 1999

MS Pharmaceutical Sciences, University of Toledo, 1997

BS Pharmaceutical Sciences, Jadavpur University, 1995

In the News

Gene therapy for sickle cell likely cost-effective at <$2M
HealthDay, 01/22/2024

Analysis: Including race in clinical algorithms can both reduce and increase health inequities — it depends on what doctors use them for 
The Conversation, 05/26/2023

536 New Coronavirus Cases In Washington; State Death Toll Drops
Patch, 09/24/2020

‘Flattening the curve’ saves more lives than thought
HealthDay News, 09/14/2020

Official Covid-19 fatalities may undercount pandemic's death toll by many hundreds in NW
KUOW, 07/15/2020

The Health 202: Why determining the coronavirus death rate is so tricky
The Washington Post, 07/10/2020

Scientists predicted that the coronavirus death rate would fall over time, but instead it doubled. Here's why it now hovers at 6%
Business Insider, 06/10/2020

8 countries have coronavirus death rates above 10%, either due to disaster or limited testing
Business Insider, 05/23/2020

UW study shows staggering numbers of US COVID-19 infection, fatality rates
KING 5, 05/23/2020

Coronavirus on track to kill 1.3 per cent of infected in US, ‘conservative’ study finds
South China Morning Post, 05/12/2020